CN1164291C - Chinese proprietary for treating protrusion of lumber interverterbral disc and its prepn. - Google Patents
Chinese proprietary for treating protrusion of lumber interverterbral disc and its prepn. Download PDFInfo
- Publication number
- CN1164291C CN1164291C CNB011096721A CN01109672A CN1164291C CN 1164291 C CN1164291 C CN 1164291C CN B011096721 A CNB011096721 A CN B011096721A CN 01109672 A CN01109672 A CN 01109672A CN 1164291 C CN1164291 C CN 1164291C
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- intervertebral disc
- lumbar intervertebral
- ramulus cinnamomi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a new medicine for curing lumbar intervertebral disk protrusion, which uses Cortex Eucommiae, Rhizoma Cibotii, radix paeoniae alba, Fructus Chaenomelis, Rhizoma Atractylodis Macrocephalae, Ramulus Cinnamomi, Caulis Spatholobi, Stigma Croci and Radix Angelicae Pubescentis as raw materials which carry out pretreatment such as pulverization, liquor extraction, drying, sterilization, etc. according to different properties of the traditional Chinese medicine, and are prepared into a pill with 3mm of phi (diameter) according to a certain proportion after screening. The present invention has a unique formula and a unique preparation method, and through years of clinical test, the curative effect is obvious.
Description
A kind of Chinese patent medicine and preparation method for the treatment of prolapse of lumbar intervertebral disc.
The invention belongs to tcm field.The present invention relates to a kind of medicine for the treatment of lumbar disc disease.Be a kind of be the Chinese patent medicine of feedstock production with the Chinese herbal medicine.The invention still further relates to the preparation method of this medicine.
Prolapse of lumbar intervertebral disc is that disease, frequently-occurring disease are seen by a kind of party, is one of higher difficult disease of sickness rate in the bone aching.Most of patients has chronic lumbar muscle strain and lumbar strain history.Its pathological characteristic is that onset is anxious, severe symptoms, if untimely treatment or malpractice can cause limbs atrophy, lower limb can not be walked.
Both at home and abroad to the Drug therapy of primary disease, there is following shortcoming at present:
1, all is based on alleviating pain, can not effectively treats, as the oral medicine of ibuprofen class to the paathogenic factor that causes prolapse of lumbar intervertebral disc;
2, the oral medicine of YAOTONGNING class has certain curative effect to the pain that prolapse of lumbar intervertebral disc causes, but obeys stimulating intestine and stomach for a long time, and side effect is arranged.
Up to the present, Chinese medicine Western medicine no matter does not also have the oral medicine of the treatment prolapse of lumbar intervertebral disc that a kind of clothes of a specified duration have no side effect evident in efficacy.
The object of the present invention is to provide a kind of muscular dystrophy, bone metabolism disturbance, impaired specific drug of spinal nerves of improving.Fundamentally suppress lumbar retrogression.This medicament is a kind of oral Chinese patent medicine agent---a granule pill.
Another object of the present invention provides this medicaments preparation method.
Solution of the present invention is based on modern medicine and traditional medicine understanding and the Therapeutic Principle to the prolapse of lumbar intervertebral disc morbidity, according to the newest fruits of modern pharmacological research, and the one group of Chinese medicine preparation that from motherland's traditional medicine treasure-house, filters out.The waist illness at first should be taken Liver and kidney into account, thus in the side with the Cortex Eucommiae, Rhizoma Cibotii invigorating the liver and kidney, strong waist knee joint is monarch with solid congenital source; Join the Fructus Chaenomelis nourishing blood to suppress the hyperactive liver with the Radix Paeoniae Alba, muscles and tendons relaxing to alleviate pain with Rhizoma Atractylodis Macrocephalae invigorating the spleen and benefiting QI granulation promoting, fills the prosperous blood of gas, joins the Caulis Spatholobi nourishing and enriching blood with Flos Carthami, makes passages through which vital energy circulates unimpeded, and it is cold to dispel the wind with Ramulus Cinnamomi, promoting flow of qi by warming channel and alleviating pain is minister altogether; Holding concurrently with the pain relieving of Radix Angelicae Pubescentis wind-damp dispelling, the behavior assistant makes under the priming.All medicines share, and play bone and muscle strengthening altogether, the effect of activating collaterals to relieve pain.To the treatment of prolapse of lumbar intervertebral disc, curative effect is reliable, and has no side effect.
Medicine of the present invention is made (consumption is a weight portion) by following component
The Cortex Eucommiae (10-30 part) Rhizoma Cibotii (8-20 part) Radix Paeoniae Alba (10-30 part) Fructus Chaenomelis (8-20 part) Rhizoma Atractylodis Macrocephalae (8-20 part) Ramulus Cinnamomi (8-20 part) Caulis Spatholobi (10-30 part) Stigma Croci (8-20 part) Radix Angelicae Pubescentis (8-20 part)
The formula optimization weight proportion scope of preparation medicine of the present invention is:
The Cortex Eucommiae (10-20 part) Rhizoma Cibotii (8-15 part) Radix Paeoniae Alba (10-20 part) Fructus Chaenomelis (8-15 part) Rhizoma Atractylodis Macrocephalae (8-15 part) Ramulus Cinnamomi (8-15 part) Caulis Spatholobi (10-20 part) Stigma Croci (8-15 part) Radix Angelicae Pubescentis (8-15 part)
The optimum weight proportioning of medicine of the present invention is:
15 parts of the Cortexs Eucommiae, 10 parts of Rhizoma Cibotii, 15 parts of the Radix Paeoniae Albas, 10 parts of Fructus Chaenomeliss, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of Ramulus Cinnamomi, 15 parts of Caulis Spatholobis, 10 parts of Stigma Crocis, 10 parts of Radix Angelicae Pubescentiss.
Above-mentioned each component is made medicine production method of the present invention is:
1, get the Cortex Eucommiae, Rhizoma Cibotii, the Radix Paeoniae Alba, Fructus Chaenomelis, the Rhizoma Atractylodis Macrocephalae, Ramulus Cinnamomi, Caulis Spatholobi, Radix Angelicae Pubescentis and be crushed to 120 order fine powders, dry back is standby.
2, get Flos Carthami and take liquid, the cool back of drying in the air is standby.
3, get the Cortex Eucommiae, Rhizoma Cibotii, the Radix Paeoniae Alba, Fructus Chaenomelis, the Rhizoma Atractylodis Macrocephalae, Ramulus Cinnamomi, Caulis Spatholobi, Radix Angelicae Pubescentis 120 order fine powders, mix, 100 ℃ of ripenings stir, sterilization in 15 minutes, get Flos Carthami and take liquid, the spray water pill, shake the about 3mm granule of system diameter pill, go into drying baker and dried 12 hours below 60 ℃, moisture content is controlled at below 9%.
Clinical drug of the present invention uses the result to show that following advantage is arranged:
1, to select the Chinese herbal medicine in the state-promulgated pharmacopoeia for use be raw material in the present invention, and each component meets the regulation of pharmaceutical control and administration rules, utilizes the comprehensive function treatment prolapse of lumbar intervertebral disc of Chinese medicine compound, nontoxic to human body.
2, medicine of the present invention need not decoct, mouthfeel delicate fragrance, and no bitterness sense, taking convenience meets the national health rules.
3, medicine of the present invention has changed the non-operative treatment prolapse of lumbar intervertebral disc, and except analgesia, the available situation of no medicine has improved the cure rate of Drug therapy prolapse of lumbar intervertebral disc greatly.
The 100 routine prolapse of lumbar intervertebral disc cases (all derive from outpatient service) of medicine of the present invention through controlling are divided into medication therapy groups of the present invention and " YAOTONGNING " positive treatment matched group at random.70 examples are organized in treatment, male 37 examples, women 33 examples.Wherein, 17 examples below 31 years old, 41-50 year 19 examples, 51-60 year 14 examples, 61-65 year 8 examples, 41.2 years old mean age.The course of disease is the longest 19 years, and the shortest 2 months, average course of disease 2.7 years.Wherein, waist 3,4 intervertebral disk hernia 7 examples, waist 4,5 intervertebral disk hernia 46 examples, waist 5 sacrums 1 intervertebral disk hernia 18 examples.Matched group 30 examples, wherein, male's 18 examples, women's 12 examples.4 examples below 31 years old, 4 examples below 31 years old, 31-40 year 7 examples, 41-50 year 9 examples, 51-60 year 6 examples, 61-65 year 4 examples, 44.3 years old mean age.The course of disease is the longest 17 years, and the shortest 3 months, average course of disease 2.4 years.Wherein, waist 3,4 intervertebral disk hernia 3 examples, waist 4,5 intervertebral disk hernia 3 examples, waist 4,5 intervertebral disc public security bureaus go out 18 examples, waist 5 sacrums 1 intervertebral disk hernia 9 examples.Two groups of patients no significant difference (P＞0.05) aspect age, sex, the course of disease, typing.Companion's sexual impotence 4 people in the treatment group, companion neurasthenia 9 people, companion's climacteric syndrome 11 people, companion's knee-joint pain 14 people, companion's talalgia 6 people.
2. diagnostic criteria:
2.1. include test case standard in: develop and publish (1997) new Chinese medicine clinical research with reference to Ministry of Health of the People's Republic of China and refer to that prolapse of lumbar intervertebral disc diagnosis typing standard is made a definite diagnosis in the guideline.All are observed case and all confirm through X line, the diagnosis of CT sheet.
2.2. elimination test case standard: all ages are associated with serious primary disease such as cardiovascular, cerebrovascular, Liver and kidney and hemopoietic system, the psychotic at under-18s or over-65s; Medication person in accordance with regulations not; The infull person of data.
3. Therapeutic Method
Separate 3.1. the rule of treatment is square, take medicine of the present invention, a 9g, a twice-daily, oral.During treatment, withdraw the other medicines of all treatment primary disease, per 20 days is further consultation 1 course of treatment, and the record subjective symptoms is added up curative effect after serveing on 2 months.
3.2. matched group is selected YAOTONGNING for use, 5 a * 0.3g is once-a-day, oral.Per 20 days is further consultation 1 course of treatment, and the record subjective symptoms is added up curative effect after serveing on 2 months.
4. curative effect determinate standard
Develop and publish prolapse of lumbar intervertebral disc efficacy assessment standard evaluation in (1997) new Chinese medicine clinical research guideline with reference to Ministry of Health of the People's Republic of China.
Cure: lumbago and skelalgia disappears substantially, and the straight-leg raising test feminine gender is recovered operate as normal.
Produce effects: flank pain partly disappears, and does not have obvious pressure pain point, and the straight-leg raising test feminine gender is recovered operate as normal substantially.
Effectively: slight lumbago and skelalgia is arranged, and straight lower limb is raised probable positive, not competent work.
Invalid: lumbago and skelalgia does not have improvement, the straight-leg raising test positive, not competent work.
5. therapeutic outcome:
Treat by clinical design, the result learns processing by statistics, sees Table 1.
Table 1
| Group example number (n) | Therapeutic effect | ||||
| Cure (n; %) | Produce effects (n; %) | Effective (n; %) | Invalid (n; %) | Total effective rate (%) | |
| Matched group 30 treatment groups 70 | 8 26.0 37 52.0¨ | 5 40.0 14 72.0¨ | 6 63.3 13 91.4 | 11 36.7 6 8.6 | 63.3 91.4¨ |
Table 1 as seen, medicine of the present invention is to the cure rate 52% of prolapse of lumbar intervertebral disc, obvious effective rate 72%, total effective rate 91.4% is compared with the Yaotongning medicine treatment of control group, and significant difference (¨ P＜0.01) is all arranged.
Claims (5)
1, a kind of medicine for the treatment of prolapse of lumbar intervertebral disc is characterized in that: it is the medicament of being made by the following weight proportion raw material:
Cortex Eucommiae 10-30 part Rhizoma Cibotii 8-20 part Radix Paeoniae Alba 10-30 part
Fructus Chaenomelis 8-20 part Rhizoma Atractylodis Macrocephalae 8-20 part Ramulus Cinnamomi 8-20 part
Caulis Spatholobi 10-30 part Stigma Croci 8-20 part Radix Angelicae Pubescentis 8-20 part.
2, the medicine of treatment prolapse of lumbar intervertebral disc according to claim 1, wherein the weight proportion of each raw material is:
Cortex Eucommiae 10-20 part Rhizoma Cibotii 8-15 part Radix Paeoniae Alba 10-20 part
Fructus Chaenomelis 8-15 part Rhizoma Atractylodis Macrocephalae 8-15 part Ramulus Cinnamomi 8-15 part
Caulis Spatholobi 10-20 part Stigma Croci 8-15 part Radix Angelicae Pubescentis 8-15 part.
3, the medicine of treatment prolapse of lumbar intervertebral disc according to claim 1, wherein the weight proportion of each raw material is:
10 parts of 10 parts of Rhizoma Atractylodis Macrocephalaes of 15 parts of Rhizoma Cibotii of the Cortex Eucommiae, 10 portions of Radix Paeoniae Albas, 15 Fructus Chaenomeliss
10 parts of 10 parts of Radix Angelicae Pubescentiss of 15 parts of Stigma Crocis of 10 portions of Caulis Spatholobis of Ramulus Cinnamomi.
4, according to the medicine of claim 1,2 or 3 described treatment prolapse of lumbar intervertebral disc, it is characterized in that: said medicament is pill or granule.
5, the preparation method of the medicine of treatment prolapse of lumbar intervertebral disc according to claim 4 is characterized in that the following step:
(1) get the Cortex Eucommiae, Rhizoma Cibotii, the Radix Paeoniae Alba, Fructus Chaenomelis, the Rhizoma Atractylodis Macrocephalae, Ramulus Cinnamomi, Caulis Spatholobi, Radix Angelicae Pubescentis and be crushed to 120 order fine powders, dry back is standby;
(2) get Flos Carthami and take liquid, the cool back of drying in the air is standby;
(3) get the Cortex Eucommiae, Rhizoma Cibotii, the Radix Paeoniae Alba, Fructus Chaenomelis, the Rhizoma Atractylodis Macrocephalae, Ramulus Cinnamomi, Caulis Spatholobi, Radix Angelicae Pubescentis 120 order fine powders, mix, 100 ℃ of ripenings stir, sterilization in 15 minutes, get the liquid that Flos Carthami takes, the spray water pill, shake the particulate pill of the system about 3mm of diameter, go into drying baker and dried 12 hours below 60 ℃, moisture content is controlled at below 9%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011096721A CN1164291C (en) | 2001-03-16 | 2001-03-16 | Chinese proprietary for treating protrusion of lumber interverterbral disc and its prepn. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011096721A CN1164291C (en) | 2001-03-16 | 2001-03-16 | Chinese proprietary for treating protrusion of lumber interverterbral disc and its prepn. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1375308A CN1375308A (en) | 2002-10-23 |
| CN1164291C true CN1164291C (en) | 2004-09-01 |
Family
ID=4658073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011096721A Expired - Fee Related CN1164291C (en) | 2001-03-16 | 2001-03-16 | Chinese proprietary for treating protrusion of lumber interverterbral disc and its prepn. |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1164291C (en) |
-
2001
- 2001-03-16 CN CNB011096721A patent/CN1164291C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1375308A (en) | 2002-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101062194A (en) | Medicine for treating bone disease and fracture and the preparing method thereof | |
| CN1907410A (en) | Chinese traditional medicine preparation for treating bone fracture and traumatic injury | |
| CN1555857A (en) | Medicinal plaster for treating sinew and bone tissue injury pain, bone fracture, dislocation | |
| CN1846781B (en) | Medicine for treating chronic pharyngitis | |
| CN102078586A (en) | Medicament for treating cervical spondylosis | |
| CN1164291C (en) | Chinese proprietary for treating protrusion of lumber interverterbral disc and its prepn. | |
| CN114652674A (en) | Blood circulation promoting and pain relieving ointment and preparation method thereof | |
| CN1857636A (en) | Chinese medicine capsule for treating protrusion of intervertebral disc and hyperosteogeny | |
| CN1895593A (en) | Medicine for treating acne and its preparation | |
| CN1131051C (en) | medicine for treating cervical spondylosis and preparation method thereof | |
| CN102552724B (en) | Chinese medicine composite for curing hypertension | |
| CN1843492A (en) | Traditional Chinese medicine preparation for treating mammary gland hyperplasia | |
| CN1544019A (en) | Chinese traditional medicine composition for treating arthralgia syndrome of cervical spondylopathy and its preparation | |
| CN1192365A (en) | Traditional Chinese medicine for treating mastosis | |
| CN1840146A (en) | Medicament for treating vitiligo | |
| CN101698074A (en) | Medicine for treating soft tissue pain and preparation method thereof | |
| CN1720937A (en) | Capsule for treating rheumatism and rheumatoid diseases and scapulohumeral periarthritis and preparation method thereof | |
| CN1272053C (en) | Chinese medicine for treating tuberculosis and its prepn and use | |
| CN101983681A (en) | Medicament for treating abnormal leucorrhea | |
| CN1319559C (en) | Pharmaceutical composition for treating muscle and bone pain and preparation method thereof | |
| CN1076622C (en) | Chinese medicine for curing nephritis | |
| CN1846767A (en) | Chinese medicine bolus for treating protrusion of lumbar intervertebral disc | |
| CN1382466A (en) | Bone setting machine | |
| CN100335112C (en) | Chinese medicine for treating kidney vacuity lumbar pain and preparation method of its capsule | |
| CN1739540A (en) | Application of arctiin in preparing medicine for treating rhinitis and nasosinusitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Yang Qu Document name: payment instructions |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Yang Qu Document name: Notification of Termination of Patent Right |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |